🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders

RecruitingNAAges 18 Years - anyAllprof. dr. Rik Schrijvers
NCT07261891 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Cases (A): adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway. * Controls (B): participants eligible for inclusion in this study must fall in one of the following categories: * Healthy controls (without immune-mediated disease) Exclusion Criteria: * Children (\< 18 years at time of recruitment) * Persons unable or unwilling to give informed consent
💊

What it tests

  • blood sampling
📍

Where

1 site
University Hospitals Leuven,
Leuven, Belgium
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy